Developing new drugs is a lengthy, expensive, high-risk process. Only 14% of drugs that get to the phase of clinical trials eventually win approval from the FDA, and the cost to bring a drug from R&D to marketing averages around $3 billion. Even after launch, close to half of new drugs underperform compared to analyst expectations.

To better understand the decisions and processes underlying these outcomes—and to help the industry improve its success rate—Catalent and BioPharma Dive’s Brand Studio conducted an exclusive survey of pharma industry professionals.

Pharma execs identified the top success factors for new drugs, revealed specific issues that hurt new treatment performance, and suggested practical solutions for optimizing the drug development process.

This webinar will provide an exclusive first look at the survey data and will give you insights to help optimize your next drug's performance in the real world.

Register Now